Considering these previous findings, IFI44L might be a promising agent serving as a tumor suppressor in oral squamous cell carcinoma, possibly through acting on the FRS-mediated FGFR1, FGFR3, and downstream signaling pathways. Here, IFI44L is linked to neoplasm.